September 30, 2026 — RNews

#treatment — Wednesday, September 30, 2026 (1 items)

hot top new

← prev day next day →

2

8 weeks versus 12 weeks of sofosbuvir-velpatasvir for treatment-naive, non-cirrhotic, chronic hepatitis C (RESOLVE): a multicentre, open-label, non-inferiority, randomised controlled trial in India. (linkinghub.elsevier.com)

Goel A … Aggarwal R The Lancet 2026-09-30

#hepatitis c #clinical trial #antiviral #treatment #viremia